Wall Street can now get exposure to $INJ without ever touching a crypto wallet. 👀

The first U.S. spot staked INJ ETF has officially launched on Nasdaq.

Ticker: $INJC

But this isn't just another crypto ETF. There's something much more interesting about how this one works.

Let's break it down. 🧵👇

𝐒𝐨, 𝐰𝐡𝐚𝐭 𝐢𝐬 $𝐈𝐍𝐉𝐂?

Think of it as a bridge between traditional investing and Injective.

Instead of buying INJ on a crypto exchange, you can purchase shares of the Canary Staked INJ ETF through a regular brokerage account.

No wallet.
No seed phrase.
No need to manage your own staking.

The fund holds actual INJ, and its share value is designed to reflect the value of those holdings, minus expenses.

Simple enough. But here's where things get interesting. 👇

𝐓𝐡𝐢𝐬 𝐢𝐬𝐧'𝐭 𝐚 𝐫𝐞𝐠𝐮𝐥𝐚𝐫 𝐬𝐩𝐨𝐭 𝐄𝐓𝐅.

$INJC is designed to stake most of the INJ held by the fund.

Here's what that means:

• The fund holds real INJ.
• It aims to stake at least 90% of its holdings under normal circumstances.
• Those tokens help secure the Injective network through proof-of-stake validation.
• The staking rewards, after applicable fees, are reflected in the fund's value.

In simple terms, the fund doesn't just hold INJ. It also puts much of it to work.

And investors get that exposure without having to stake anything themselves.

𝐁𝐮𝐭 𝐭𝐡𝐞𝐫𝐞'𝐬 𝐚 𝐜𝐚𝐭𝐜𝐡. 👀

Convenience isn't free.

Here's what investors need to understand:

• 1.10% annual sponsor fee.
• Separate staking-related fees reduce the rewards earned by the fund.
• Injective has a 21-day unbonding period, which affects how quickly staked INJ can become liquid.
• You own ETF shares, NOT actual INJ tokens.

That means you cannot withdraw your INJC shares as INJ, use them on Injective, or participate directly in onchain governance.

You're buying exposure, not self-custody.

𝐖𝐡𝐲 𝐝𝐨𝐞𝐬 𝐭𝐡𝐢𝐬 𝐦𝐚𝐭𝐭𝐞𝐫 𝐟𝐨𝐫 $𝐈𝐍𝐉?

For years, traditional investors who wanted INJ exposure had to navigate crypto exchanges, wallets, private keys, and staking.

That barrier is now much lower.

A traditional investor can access INJ through a familiar brokerage structure.

This potentially opens the door to a new pool of capital that previously found direct crypto ownership too complicated or restrictive.

And if the fund attracts sustained inflows, its purchases and staking activity could create additional demand for INJ.

That's the bigger opportunity.

𝐃𝐨𝐞𝐬 𝐭𝐡𝐢𝐬 𝐦𝐞𝐚𝐧 $𝐈𝐍𝐉 𝐢𝐬 𝐠𝐨𝐢𝐧𝐠 𝐭𝐨 𝐦𝐨𝐨𝐧?

Not necessarily.

An ETF launch doesn't guarantee inflows, and inflows don't guarantee price appreciation.

The fund also comes with fees, staking risks, and exposure to INJ's price volatility.

The Injective Foundation indicated an intention to purchase up to $15M in seed shares.

That's a notable starting point, but the real story will be what happens after launch.

𝐇𝐞𝐫𝐞'𝐬 𝐰𝐡𝐚𝐭 𝐈'𝐦 𝐰𝐚𝐭𝐜𝐡𝐢𝐧𝐠:

👀 Consistent capital inflows into $INJC.

📈 Growth in the fund's INJ holdings.

🔒 How much of its INJ remains staked over time.

🏦 Whether other institutional products and ETF issuers follow.

Injective has spent years building financial infrastructure onchain.

Now, traditional investors have another route to access the asset powering that ecosystem.

The infrastructure is being built. The access is expanding.

The next question is how much capital will actually follow.

$INJ $INJC